Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)
Year: 2022
Type: article
Source: Blood
Authors: Hun Lee, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, Yuliya Linhares, Paul Alan Gonzales, Mihir Raval, Rangaswamy Chintapatla, Tatyana Feldman, Habte Yimer, Miguel Islas-Ohlmayer, Asad Dean, Vishal Rana, Mitul Gandhi, John Renshaw, Linda Ho, Michelle A. Fanale, Wenchuan Guo, Christopher A. Yasenchak
Institutions: The University of Texas MD Anderson Cancer Center, Sarah Cannon, Tennessee Oncology, The US Oncology Network, University of Tennessee at Knoxville, University Hospitals Seidman Cancer Center, Kadlec Clinic, Hackensack Meridian Health, Oncology Hematology Care, Seagen (United States), Willamette Valley Cancer Institute and Research Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310113752